Abivax Stock Nears +3% and Challenges Resistance
The French biotech continues its upward trend during the session, following several days of turmoil around its quarterly earnings. The stock reached a new intraday peak, before slightly retracting below the closely watched resistance levels. It is among the top gainers in the SBF 120 at midday.
Abivax Climbs to €117.50 Before Retreating at Its €115.10 Resistance
Abivax stock gains 2.31% at €115.00 midday, after climbing to €117.50 during the session. The stock broke above its €115.10 resistance before settling exactly at this threshold. Over the week, the stock has gained 11.76%, roughly the same magnitude as the quarterly gain (+12.09%), indicating that almost all of the movement in the last three months was concentrated in recent sessions. Over a year, the performance remains exceptional, at over 2,100%. The stock is now trading above its three moving averages, with a gap of 10.67% over the MM20 and 23.18% over the MM200, confirming a bullish medium-term orientation. The RSI at 60 remains in the neutral zone, with no immediate overheating signal, allowing the stock to technically align with its resistance without hitting it. Abivax is among the top gainers in the SBF 120, in an index that is down 0.32%.
Cash Reserves of €491.6 Million Cover Development Until the Fourth Quarter of 2027
The rebound follows the quarterly publication. During the Q1 2026 report (May 22, 2026), Abivax confirmed the sustained efficacy of obefazimod in ulcerative colitis, with 68% of patients in clinical remission at three years on a reduced dose and no new safety signals over seven years. However, the operating loss widened to €56.2 million, from €47.2 million a year earlier, due to an increase of €10.2 million in R&D expenses. The company has a cash reserve of €491.6 million, which provides visibility until the fourth quarter of 2027 according to the details shared during the publication. The next clinical milestone mentioned by the company on this occasion is the launch of a phase 3 maintenance trial ABTECT in UC, expected by the end of the second quarter of 2026. The intraday breach of the €115.10 resistance, followed by a precise return to this level, makes the stock's behavior around this threshold the next technical reference to watch.
